{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:47:04Z","timestamp":1794538024157,"version":"4.9.1"},"reference-count":210,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","award":["NCC-19112605"],"award-info":[{"award-number":["NCC-19112605"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00213292"],"award-info":[{"award-number":["RS-2023-00213292"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00405650"],"award-info":[{"award-number":["RS-2024-00405650"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NRF, BK FOUR"},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["BK FOUR"],"award-info":[{"award-number":["BK FOUR"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The tumour microenvironment imposes severe metabolic constraints that reshape anti-tumour immunity across the cancer-immunity cycle. Rather than serving merely as passive byproducts of tumour growth, tumour-derived metabolites and nutrient imbalances act as potent metabolic checkpoints\u2212stage-specific barriers that disrupt the functional progression of dendritic cells (DCs) and T cells from antigen presentation to effective tumour clearance. In this review, we propose a framework that overlays the cancer-immunity cycle with major metabolic checkpoints, including glucose and amino acid competition, acidosis and lipid overload, to clarify how distinct metabolic stresses create immune bottlenecks at different stages of the anti-tumour response. We then discuss how distinct tumour metabolic phenotypes, characterized by high glycolysis, amino acid dependency or lipid dysregulation, generate local environmental stresses that differentially reprogram DC function and T cell fitness. Particular emphasis is placed on the DC\u2013T cell axis as a critical site where multiple metabolic defects converge, destabilizing antigen presentation, co-stimulation and immunological synapse function. We further survey emerging therapeutic strategies aimed at restoring the DC\u2013T cell axis and effective anti-tumour immunity, ranging from small-molecule metabolic inhibitors to metabolically engineered adoptive cell therapies designed to function in hostile microenvironments. Finally, we highlight emerging technologies such as single-cell and spatial multi-omics, real-time metabolic imaging and microphysiological systems that can resolve the spatiotemporal heterogeneity of tumour immunometabolism and support more precise immunometabolic interventions.<\/jats:p>","DOI":"10.1038\/s12276-026-01798-w","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T06:19:02Z","timestamp":1785997142000},"page":"2470-2490","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metabolic rewiring of the dendritic cell\u2013T cell axis: tumour-derived barriers and therapeutic opportunities"],"prefix":"10.1038","volume":"58","author":[{"given":"Minkyu","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2668-7528","authenticated-orcid":false,"given":"Minkyung","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"1798_CR1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"EN Arner","year":"2023","unstructured":"Arner, E. N. & Rathmell, J. C. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell 41, 421\u2013433 (2023).","journal-title":"Cancer Cell"},{"key":"1798_CR2","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman, I., Chen, D. S., Powles, T. & Turley, S. J. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity 56, 2188\u20132205 (2023).","journal-title":"Immunity"},{"key":"1798_CR3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.it.2021.09.002","volume":"42","author":"LF Somarribas Patterson","year":"2021","unstructured":"Somarribas Patterson, L. F. & Vardhana, S. A. Metabolic regulation of the cancer-immunity cycle. Trends Immunol. 42, 975\u2013993 (2021).","journal-title":"Trends Immunol."},{"key":"1798_CR4","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete, A. et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol. Immunol. 20, 432\u2013447 (2023).","journal-title":"Cell Mol. Immunol."},{"key":"1798_CR5","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41556-022-01002-x","volume":"24","author":"KC Kao","year":"2022","unstructured":"Kao, K. C., Vilbois, S., Tsai, C. H. & Ho, P. C. Metabolic communication in the tumour-immune microenvironment. Nat. Cell Biol. 24, 1574\u20131583 (2022).","journal-title":"Nat. Cell Biol."},{"key":"1798_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1744671","volume":"17","author":"B Zhang","year":"2026","unstructured":"Zhang, B. et al. Glycolysis in the tumor microenvironment shapes dendritic cell function and antitumor immunity. Front. Immunol. 17, 1744671 (2026).","journal-title":"Front. Immunol."},{"key":"1798_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41423-021-00753-1","volume":"19","author":"SH M\u00f8ller","year":"2022","unstructured":"M\u00f8ller, S. H., Wang, L. & Ho, P.-C. Metabolic programming in dendritic cells tailors immune responses and homeostasis. Cell. Mol. Immunol. 19, 370\u2013383 (2022).","journal-title":"Cell. Mol. Immunol."},{"key":"1798_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1626973","volume":"16","author":"S Chen","year":"2025","unstructured":"Chen, S. et al. Regulation of dendritic cell biology by amino acids and their transporters. Front. Immunol. 16, 1626973 (2025).","journal-title":"Front. Immunol."},{"key":"1798_CR9","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1016\/j.apsb.2023.12.004","volume":"14","author":"L Wang","year":"2024","unstructured":"Wang, L. et al. The inhibitory effect of adenosine on tumor adaptive immunity and intervention strategies. Acta Pharm. Sin. B. 14, 1951\u20131964 (2024).","journal-title":"Acta Pharm. Sin. B."},{"key":"1798_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.691134","volume":"12","author":"I Manoharan","year":"2021","unstructured":"Manoharan, I., Prasad, P. D., Thangaraju, M. & Manicassamy, S. Lactate-dependent regulation of immune responses by dendritic cells and macrophages. Front. Immunol. 12, 691134 (2021).","journal-title":"Front. Immunol."},{"key":"1798_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02186-9","volume":"8","author":"F Veglia","year":"2017","unstructured":"Veglia, F. et al. Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer. Nat. Commun. 8, 2122 (2017).","journal-title":"Nat. Commun."},{"key":"1798_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2026.100990","volume":"67","author":"N Srivastava","year":"2026","unstructured":"Srivastava, N. & Wan, X. From damage signals to immune modulators: oxidized lipids in immunometabolic inflammation. J. Lipid Res. 67, 100990 (2026).","journal-title":"J. Lipid Res."},{"key":"1798_CR13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41423-024-01148-8","volume":"21","author":"S Ma","year":"2024","unstructured":"Ma, S., Ming, Y., Wu, J. & Cui, G. Cellular metabolism regulates the differentiation and function of T-cell subsets. Cell Mol. Immunol. 21, 419\u2013435 (2024).","journal-title":"Cell Mol. Immunol."},{"key":"1798_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adf4726","volume":"10","author":"V Bhandarkar","year":"2025","unstructured":"Bhandarkar, V., Dinter, T. & Spranger, S. Architects of immunity: how dendritic cells shape CD8+ T cell fate in cancer. Sci. Immunol. 10, eadf4726 (2025).","journal-title":"Sci. Immunol."},{"key":"1798_CR15","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-18-2882","volume":"25","author":"BW Labadie","year":"2019","unstructured":"Labadie, B. W., Bao, R. & Luke, J. J. Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis. Clin. Cancer Res. 25, 1462\u20131471 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1798_CR16","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","volume":"22","author":"DH Munn","year":"2005","unstructured":"Munn, D. H. et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22, 633\u2013642 (2005).","journal-title":"Immunity"},{"key":"1798_CR17","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.molcel.2020.09.006","volume":"80","author":"W Wang","year":"2020","unstructured":"Wang, W. & Zou, W. Amino acids and their transporters in T cell immunity and cancer therapy. Mol. Cell 80, 384\u2013395 (2020).","journal-title":"Mol. Cell"},{"key":"1798_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46377-7","volume":"15","author":"L Simula","year":"2024","unstructured":"Simula, L. et al. Mitochondrial metabolism sustains CD8+ T cell migration for an efficient infiltration into solid tumors. Nat. Commun. 15, 2203 (2024).","journal-title":"Nat. Commun."},{"key":"1798_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2020.100888","volume":"77","author":"J Vuononvirta","year":"2021","unstructured":"Vuononvirta, J., Marelli-Berg, F. M. & Poobalasingam, T. Metabolic regulation of T lymphocyte motility and migration. Mol. Aspects Med. 77, 100888 (2021).","journal-title":"Mol. Aspects Med."},{"key":"1798_CR20","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/nri2400","volume":"8","author":"J Rivera","year":"2008","unstructured":"Rivera, J., Proia, R. L. & Olivera, A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat. Rev. Immunol. 8, 753\u2013763 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"1798_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1002202","volume":"13","author":"R Haas","year":"2015","unstructured":"Haas, R. et al. Lactate regulates metabolic and pro-inflammatory circuits in control of T cell migration and effector functions. PLoS Biol. 13, e1002202 (2015).","journal-title":"PLoS Biol."},{"key":"1798_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.omtm.2021.03.001","volume":"21","author":"HS Newton","year":"2021","unstructured":"Newton, H. S., Chimote, A. A., Arnold, M. J., Wise-Draper, T. M. & Conforti, L. Targeted knockdown of the adenosine A2A receptor by lipid NPs rescues the chemotaxis of head and neck cancer memory T cells. Mol. Ther. Methods Clin. Dev. 21, 133\u2013143 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1798_CR23","doi-asserted-by":"publisher","unstructured":"Chimote, A. A. A defect in KCa3.1 channel activity limits the ability of CD8+ T cells from cancer patients to infiltrate an adenosine-rich microenvironment. Sci. Signal 11, https:\/\/doi.org\/10.1126\/scisignal.aaq1616 (2018).","DOI":"10.1126\/scisignal.aaq1616"},{"key":"1798_CR24","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nature19364","volume":"537","author":"R Eil","year":"2016","unstructured":"Eil, R. et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537, 539\u2013543 (2016).","journal-title":"Nature"},{"key":"1798_CR25","doi-asserted-by":"publisher","unstructured":"Xiong, Y. et al. CD4 T cell sphingosine 1-phosphate receptor (S1PR)1 and S1PR4 and endothelial S1PR2 regulate afferent lymphatic migration. Sci. Immunol. 4, https:\/\/doi.org\/10.1126\/sciimmunol.aav1263 (2019).","DOI":"10.1126\/sciimmunol.aav1263"},{"key":"1798_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1\u201310 (2013).","journal-title":"Immunity"},{"key":"1798_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02332-6","volume":"10","author":"Z Chao","year":"2025","unstructured":"Chao, Z. et al. Immunological synapse: structures, molecular mechanisms and therapeutic implications in disease. Signal Transduct. Target. Ther. 10, 254 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1798_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.immuni.2012.10.020","volume":"38","author":"LA Sena","year":"2013","unstructured":"Sena, L. A. et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity 38, 225\u2013236 (2013).","journal-title":"Immunity"},{"key":"1798_CR29","doi-asserted-by":"publisher","first-page":"14418","DOI":"10.1073\/pnas.0703126104","volume":"104","author":"A Quintana","year":"2007","unstructured":"Quintana, A. et al. T cell activation requires mitochondrial translocation to the immunological synapse. Proc. Natl Acad. Sci. USA. 104, 14418\u201314423 (2007).","journal-title":"Proc. Natl Acad. Sci. USA."},{"key":"1798_CR30","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1038\/emboj.2011.25","volume":"30","author":"F Baixauli","year":"2011","unstructured":"Baixauli, F. et al. The mitochondrial fission factor dynamin-related protein 1 modulates T-cell receptor signalling at the immune synapse. EMBO J. 30, 1238\u20131250 (2011).","journal-title":"EMBO J."},{"key":"1798_CR31","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/ni.2687","volume":"14","author":"PM Gubser","year":"2013","unstructured":"Gubser, P. M. et al. Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch. Nat. Immunol. 14, 1064\u20131072 (2013).","journal-title":"Nat. Immunol."},{"key":"1798_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.589434","volume":"10","author":"AJ Fischbeck","year":"2020","unstructured":"Fischbeck, A. J. et al. Tumor lactic acidosis: protecting tumor by inhibiting cytotoxic activity through motility arrest and bioenergetic silencing. Front. Oncol. 10, 589434 (2020).","journal-title":"Front. Oncol."},{"key":"1798_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jim.2016.08.013","volume":"438","author":"PJ Siska","year":"2016","unstructured":"Siska, P. J. et al. Fluorescence-based measurement of cystine uptake through xCT shows requirement for ROS detoxification in activated lymphocytes. J. Immunol. Methods 438, 51\u201358 (2016).","journal-title":"J. Immunol. Methods"},{"key":"1798_CR34","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.immuni.2008.06.016","volume":"29","author":"M Klemke","year":"2008","unstructured":"Klemke, M. et al. Oxidation of cofilin mediates T cell hyporesponsiveness under oxidative stress conditions. Immunity 29, 404\u2013413 (2008).","journal-title":"Immunity"},{"key":"1798_CR35","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang, C. H. et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229\u20131241 (2015).","journal-title":"Cell"},{"key":"1798_CR36","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","volume":"167","author":"R Geiger","year":"2016","unstructured":"Geiger, R. et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167, 829\u2013842.e13 (2016).","journal-title":"Cell"},{"key":"1798_CR37","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","volume":"45","author":"NE Scharping","year":"2016","unstructured":"Scharping, N. E. et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45, 374\u2013388 (2016).","journal-title":"Immunity"},{"key":"1798_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7692","volume":"6","author":"N Patsoukis","year":"2015","unstructured":"Patsoukis, N. et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun. 6, 6692 (2015).","journal-title":"Nat. Commun."},{"key":"1798_CR39","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.it.2025.08.005","volume":"46","author":"AB Plata-Gomez","year":"2025","unstructured":"Plata-Gomez, A. B., Chen, W., Ho, P. C. & Ling, G. S. Mitochondrial lipid metabolism in tumor immunosurveillance and evasion. Trends Immunol. 46, 766\u2013778 (2025).","journal-title":"Trends Immunol."},{"key":"1798_CR40","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.immuni.2021.05.003","volume":"54","author":"S Xu","year":"2021","unstructured":"Xu, S. et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. Immunity 54, 1561\u20131577.e7 (2021).","journal-title":"Immunity"},{"key":"1798_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02205-6","volume":"24","author":"K Huang","year":"2025","unstructured":"Huang, K. et al. Tumor metabolic regulators: key drivers of metabolic reprogramming and the promising targets in cancer therapy. Mol. Cancer 24, 7 (2025).","journal-title":"Mol. Cancer"},{"key":"1798_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07232-8","volume":"9","author":"K Huang","year":"2018","unstructured":"Huang, K. et al. Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas. Nat. Commun. 9, 5330 (2018).","journal-title":"Nat. Commun."},{"key":"1798_CR43","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/s42255-023-00817-8","volume":"5","author":"E Benedetti","year":"2023","unstructured":"Benedetti, E. et al. A multimodal atlas of tumour metabolism reveals the architecture of gene\u2013metabolite covariation. Nat. Metab. 5, 1029\u20131044 (2023).","journal-title":"Nat. Metab."},{"key":"1798_CR44","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.cell.2017.09.019","volume":"171","author":"B Faubert","year":"2017","unstructured":"Faubert, B. et al. Lactate metabolism in human lung tumors. Cell 171, 358\u2013371.e9 (2017).","journal-title":"Cell"},{"key":"1798_CR45","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1073\/pnas.1312570111","volume":"111","author":"B Faubert","year":"2014","unstructured":"Faubert, B. et al. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1\u0251. Proc. Natl Acad. Sci. USA 111, 2554\u20132559 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1798_CR46","first-page":"2856","volume":"17","author":"X Zhou","year":"2019","unstructured":"Zhou, X. et al. Effect of PTEN loss on metabolic reprogramming in prostate cancer cells. Oncol. Lett. 17, 2856\u20132866 (2019).","journal-title":"Oncol. Lett."},{"key":"1798_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova, N. N. & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell Metab. 23, 27\u201347 (2016).","journal-title":"Cell Metab."},{"key":"1798_CR48","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1182\/blood-2005-05-1795","volume":"107","author":"E Gottfried","year":"2006","unstructured":"Gottfried, E. et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 107, 2013\u20132021 (2006).","journal-title":"Blood"},{"key":"1798_CR49","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.cell.2015.08.012","volume":"162","author":"PC Ho","year":"2015","unstructured":"Ho, P. C. et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162, 1217\u20131228 (2015).","journal-title":"Cell"},{"key":"1798_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108500","volume":"33","author":"WJ Quinn","year":"2020","unstructured":"Quinn, W. J. et al. Lactate limits T cell proliferation via the NAD(H) redox state. Cell Rep. 33, 108500 (2020).","journal-title":"Cell Rep."},{"key":"1798_CR51","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.cell.2011.03.054","volume":"145","author":"W Luo","year":"2011","unstructured":"Luo, W. et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145, 732\u2013744 (2011).","journal-title":"Cell"},{"key":"1798_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01102-5","volume":"14","author":"XC Ding","year":"2021","unstructured":"Ding, X. C. et al. The relationship between expression of PD-L1 and HIF-1\u0251 in glioma cells under hypoxia. J. Hematol. Oncol. 14, 92 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"1798_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.697894","volume":"11","author":"G Ma","year":"2021","unstructured":"Ma, G. et al. Targeted glucose or glutamine metabolic therapy combined with PD-1\/PD-L1 checkpoint blockade immunotherapy for the treatment of tumors \u2014 mechanisms and strategies. Front. Oncol. 11, 697894 (2021).","journal-title":"Front. Oncol."},{"key":"1798_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.572722","volume":"10","author":"R Xu","year":"2020","unstructured":"Xu, R. et al. Reprogramming of amino acid metabolism in pancreatic cancer: recent advances and therapeutic strategies. Front. Oncol. 10, 572722 (2020).","journal-title":"Front. Oncol."},{"key":"1798_CR55","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccr.2013.08.020","volume":"24","author":"LA Timmerman","year":"2013","unstructured":"Timmerman, L. A. et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 24, 450\u2013465 (2013).","journal-title":"Cancer Cell"},{"key":"1798_CR56","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41588-024-01662-5","volume":"56","author":"J Hu","year":"2024","unstructured":"Hu, J. et al. Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression. Nat. Genet. 56, 442\u2013457 (2024).","journal-title":"Nat. Genet."},{"key":"1798_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06435-w","volume":"15","author":"J Chen","year":"2024","unstructured":"Chen, J., Cui, L., Lu, S. & Xu, S. Amino acid metabolism in tumor biology and therapy. Cell Death Dis. 15, 42 (2024).","journal-title":"Cell Death Dis."},{"key":"1798_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1049147","volume":"13","author":"Q Ding","year":"2023","unstructured":"Ding, Q., Li, R., Wang, Q., Yu, L. & Zi, F. A pan-cancer analysis of the role of argininosuccinate synthase 1 in human tumors. Front. Oncol. 13, 1049147 (2023).","journal-title":"Front. Oncol."},{"key":"1798_CR59","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.cmet.2023.06.004","volume":"35","author":"C Xue","year":"2023","unstructured":"Xue, C. et al. Tryptophan metabolism in health and disease. Cell Metab. 35, 1304\u20131326 (2023).","journal-title":"Cell Metab."},{"key":"1798_CR60","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41416-020-01156-1","volume":"124","author":"VDB Bonifacio","year":"2021","unstructured":"Bonifacio, V. D. B., Pereira, S. A., Serpa, J. & Vicente, J. B. Cysteine metabolic circuitries: druggable targets in cancer. Br. J. Cancer 124, 862\u2013879 (2021).","journal-title":"Br. J. Cancer"},{"key":"1798_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104906","volume":"215","author":"J Lee","year":"2025","unstructured":"Lee, J. & Roh, J. L. Cysteine metabolism at the crossroads of ferroptosis and cancer therapy. Crit. Rev. Oncol. Hematol. 215, 104906 (2025).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1798_CR62","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41586-023-06299-8","volume":"620","author":"C Guo","year":"2023","unstructured":"Guo, C. et al. SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity. Nature 620, 200\u2013208 (2023).","journal-title":"Nature"},{"key":"1798_CR63","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1084\/jem.20020052","volume":"196","author":"P Terness","year":"2002","unstructured":"Terness, P. et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196, 447\u2013457 (2002).","journal-title":"J. Exp. Med."},{"key":"1798_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-022-00420-8","volume":"11","author":"S Vasseur","year":"2022","unstructured":"Vasseur, S. & Guillaumond, F. Lipids in cancer: a global view of the contribution of lipid pathways to metastatic formation and treatment resistance. Oncogenesis 11, 46 (2022).","journal-title":"Oncogenesis"},{"key":"1798_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07836-1","volume":"16","author":"F Yang","year":"2025","unstructured":"Yang, F. et al. PLIN2 promotes colorectal cancer progression through CD36-mediated epithelial-mesenchymal transition. Cell Death Dis. 16, 510 (2025).","journal-title":"Cell Death Dis."},{"key":"1798_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01498-2","volume":"16","author":"HR Jin","year":"2023","unstructured":"Jin, H. R. et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J. Hematol. Oncol. 16, 103 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"1798_CR67","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1002\/1873-3468.14193","volume":"595","author":"C Shen","year":"2021","unstructured":"Shen, C., Chen, J. H., Oh, H. R. & Park, J. H. Transcription factor SOX2 contributes to nonalcoholic fatty liver disease development by regulating the expression of the fatty acid transporter CD36. FEBS Lett. 595, 2493\u20132503 (2021).","journal-title":"FEBS Lett."},{"key":"1798_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101772","volume":"13","author":"W Zhang","year":"2026","unstructured":"Zhang, W. et al. Fatty acid metabolic reprogramming in the tumor microenvironment: Unraveling mechanisms and therapeutic prospects. Genes Dis. 13, 101772 (2026).","journal-title":"Genes Dis."},{"key":"1798_CR69","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/s41416-019-0451-4","volume":"120","author":"R Munir","year":"2019","unstructured":"Munir, R., Lisec, J., Swinnen, J. V. & Zaidi, N. Lipid metabolism in cancer cells under metabolic stress. Br. J. Cancer 120, 1090\u20131098 (2019).","journal-title":"Br. J. Cancer"},{"key":"1798_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14218-7","volume":"11","author":"C Imbert","year":"2020","unstructured":"Imbert, C. et al. Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1. Nat. Commun. 11, 437 (2020).","journal-title":"Nat. Commun."},{"key":"1798_CR71","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41423-026-01411-0","volume":"23","author":"YW Du","year":"2026","unstructured":"Du, Y. W. et al. Lipid metabolism reprogramming shapes the immune landscape in the tumor microenvironment. Cell. Mol. Immunol. 23, 457\u2013470 (2026).","journal-title":"Cell. Mol. Immunol."},{"key":"1798_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1322746","volume":"14","author":"L Xiao","year":"2023","unstructured":"Xiao, L., Xian, M., Zhang, C., Guo, Q. & Yi, Q. Lipid peroxidation of immune cells in cancer. Front. Immunol. 14, 1322746 (2023).","journal-title":"Front. Immunol."},{"key":"1798_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molmed.2015.11.003","volume":"22","author":"D Wang","year":"2016","unstructured":"Wang, D. & DuBois, R. N. The role of prostaglandin E2 in tumor-associated immunosuppression. Trends Mol. Med. 22, 1\u20133 (2016).","journal-title":"Trends Mol. Med."},{"key":"1798_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.613492","volume":"12","author":"X Peng","year":"2021","unstructured":"Peng, X., He, Y., Huang, J., Tao, Y. & Liu, S. Metabolism of dendritic cells in tumor microenvironment: for immunotherapy. Front. Immunol. 12, 613492 (2021).","journal-title":"Front. Immunol."},{"key":"1798_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32849-1","volume":"13","author":"J Adamik","year":"2022","unstructured":"Adamik, J. et al. Distinct metabolic states guide maturation of inflammatory and tolerogenic dendritic cells. Nat. Commun. 13, 5184 (2022).","journal-title":"Nat. Commun."},{"key":"1798_CR76","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1182\/blood-2012-03-419747","volume":"120","author":"B Everts","year":"2012","unstructured":"Everts, B. et al. Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood 120, 1422\u20131431 (2012).","journal-title":"Blood"},{"key":"1798_CR77","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.it.2019.06.004","volume":"40","author":"P Giovanelli","year":"2019","unstructured":"Giovanelli, P., Sandoval, T. A. & Cubillos-Ruiz, J. R. Dendritic cell metabolism and function in tumors. Trends Immunol. 40, 699\u2013718 (2019).","journal-title":"Trends Immunol."},{"key":"1798_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071525","volume":"13","author":"FJ Cueto","year":"2021","unstructured":"Cueto, F. J. & Sancho, D. The Flt3L\/Flt3 axis in dendritic cell biology and cancer immunotherapy. Cancers 13, 1525 (2021).","journal-title":"Cancers"},{"key":"1798_CR79","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41422-019-0161-8","volume":"29","author":"LR Pelgrom","year":"2019","unstructured":"Pelgrom, L. R. et al. LKB1 expressed in dendritic cells governs the development and expansion of thymus-derived regulatory T cells. Cell Res. 29, 406\u2013419 (2019).","journal-title":"Cell Res."},{"key":"1798_CR80","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.cell.2015.05.025","volume":"161","author":"JR Cubillos-Ruiz","year":"2015","unstructured":"Cubillos-Ruiz, J. R. et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161, 1527\u20131538 (2015).","journal-title":"Cell"},{"key":"1798_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15620","volume":"8","author":"SJ Lawless","year":"2017","unstructured":"Lawless, S. J. et al. Glucose represses dendritic cell-induced T cell responses. Nat. Commun. 8, 15620 (2017).","journal-title":"Nat. Commun."},{"key":"1798_CR82","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.it.2016.08.009","volume":"37","author":"N Sukhbaatar","year":"2016","unstructured":"Sukhbaatar, N., Hengstschl\u00e4ger, M. & Weichhart, T. mTOR-mediated regulation of dendritic cell differentiation and function. Trends Immunol. 37, 778\u2013789 (2016).","journal-title":"Trends Immunol."},{"key":"1798_CR83","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002155","volume":"9","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity. J. Immunother. Cancer 9, e002155 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1798_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103627","volume":"73","author":"Z-H Wang","year":"2021","unstructured":"Wang, Z.-H., Peng, W.-B. & Zhou, Q. Lactate in the tumour microenvironment: from immune modulation to therapy. EBioMedicine 73, 103627 (2021).","journal-title":"EBioMedicine"},{"key":"1798_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01151-3","volume":"7","author":"X Li","year":"2022","unstructured":"Li, X. et al. Lactate metabolism in human health and disease. Signal Transduct. Target. Ther. 7, 305 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1798_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092403","author":"S Burgdorf","year":"2020","unstructured":"Burgdorf, S., Porubsky, S., Marx, A. & Popovic, Z. V. Cancer acidity and hypertonicity contribute to dysfunction of tumor-associated dendritic cells: potential impact on antigen cross-presentation machinery. Cancers https:\/\/doi.org\/10.3390\/cancers12092403 (2020).","journal-title":"Cancers"},{"key":"1798_CR87","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1158\/0008-5472.CAN-17-1307","volume":"78","author":"N Caronni","year":"2018","unstructured":"Caronni, N. et al. Downregulation of membrane trafficking proteins and lactate conditioning determine loss of dendritic cell function in lung cancer. Cancer Res. 78, 1685\u20131699 (2018).","journal-title":"Cancer Res."},{"key":"1798_CR88","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.cmet.2019.11.011","volume":"30","author":"E Marin","year":"2019","unstructured":"Marin, E. et al. Human tolerogenic dendritic cells regulate immune responses through lactate synthesis. Cell Metab. 30, 1075\u20131090.e8 (2019).","journal-title":"Cell Metab."},{"key":"1798_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-025-02460-1","volume":"24","author":"H Zhang","year":"2025","unstructured":"Zhang, H. et al. Immunometabolism: crosstalk with tumor metabolism and implications for cancer immunotherapy. Mol. Cancer 24, 1\u201343 (2025).","journal-title":"Mol. Cancer"},{"key":"1798_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01565","volume":"10","author":"G Mondanelli","year":"2019","unstructured":"Mondanelli, G., Iacono, A., Allegrucci, M., Puccetti, P. & Grohmann, U. Immunoregulatory interplay between arginine and tryptophan metabolism in health and disease. Front. Immunol. 10, 1565 (2019).","journal-title":"Front. Immunol."},{"key":"1798_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00274","volume":"3","author":"SV Schmidt","year":"2012","unstructured":"Schmidt, S. V., Nino-Castro, A. C. & Schultze, J. L. Regulatory dendritic cells: there is more than just immune activation. Front. Immunol. 3, 274 (2012).","journal-title":"Front. Immunol."},{"key":"1798_CR92","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/0394632016678873","volume":"30","author":"PU Simioni","year":"2017","unstructured":"Simioni, P. U., Fernandes, L. G. & Tamashiro, W. M. Downregulation of L-arginine metabolism in dendritic cells induces tolerance to exogenous antigen. Int. J. Immunopathol. Pharmacol. 30, 44\u201357 (2017).","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"1798_CR93","doi-asserted-by":"publisher","DOI":"10.3892\/or.2025.8919","volume":"54","author":"J Zhao","year":"2025","unstructured":"Zhao, J. et al. Tryptophan metabolism: from physiological functions to key roles and therapeutic targets in cancer. Oncol. Rep. 54, 86 (2025).","journal-title":"Oncol. Rep."},{"key":"1798_CR94","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.4049\/jimmunol.1001199","volume":"185","author":"JA D\u2019Angelo","year":"2010","unstructured":"D\u2019Angelo, J. A. et al. The cystine\/glutamate antiporter regulates dendritic cell differentiation and antigen presentation. J. Immunol. 185, 3217\u20133226 (2010).","journal-title":"J. Immunol."},{"key":"1798_CR95","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/jcp.21366","volume":"215","author":"M Lo","year":"2008","unstructured":"Lo, M., Wang, Y. Z. & Gout, P. W. The xc- cystine\/glutamate antiporter: a potential target for therapy of cancer and other diseases. J. Cell. Physiol. 215, 593\u2013602 (2008).","journal-title":"J. Cell. Physiol."},{"key":"1798_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13050986","author":"NS Aboelella","year":"2021","unstructured":"Aboelella, N. S., Brandle, C., Kim, T., Ding, Z. C. & Zhou, G. Oxidative stress in the tumor microenvironment and its relevance to cancer immunotherapy. Cancers https:\/\/doi.org\/10.3390\/cancers13050986 (2021).","journal-title":"Cancers"},{"key":"1798_CR97","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/nm.2172","volume":"16","author":"DL Herber","year":"2010","unstructured":"Herber, D. L. et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat. Med. 16, 880\u2013886, https:\/\/doi.org\/10.1038\/nm.2172 (2010).","journal-title":"Nat. Med."},{"key":"1798_CR98","doi-asserted-by":"publisher","first-page":"5498","DOI":"10.1182\/blood-2011-07-365825","volume":"118","author":"N Obermajer","year":"2011","unstructured":"Obermajer, N., Muthuswamy, R., Lesnock, J., Edwards, R. P. & Kalinski, P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 118, 5498\u20135505 (2011).","journal-title":"Blood"},{"key":"1798_CR99","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3892\/ijmm.2020.4801","volume":"47","author":"G Diao","year":"2021","unstructured":"Diao, G. et al. Prostaglandin E2 serves a dual role in regulating the migration of dendritic cells. Int. J. Mol. Med. 47, 207\u2013218 (2021).","journal-title":"Int. J. Mol. Med."},{"key":"1798_CR100","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41590-024-02065-8","volume":"26","author":"M Belabed","year":"2025","unstructured":"Belabed, M. et al. Cholesterol mobilization regulates dendritic cell maturation and the immunogenic response to cancer. Nat. Immunol. 26, 188\u2013199 (2025).","journal-title":"Nat. Immunol."},{"key":"1798_CR101","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev-physiol-031620-093815","volume":"83","author":"B Chaurasia","year":"2021","unstructured":"Chaurasia, B. & Summers, S. A. Ceramides in metabolism: key lipotoxic players. Annu. Rev. Physiol. 83, 303\u2013330 (2021).","journal-title":"Annu. Rev. Physiol."},{"key":"1798_CR102","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.4049\/jimmunol.167.7.3773","volume":"167","author":"T Kanto","year":"2001","unstructured":"Kanto, T., Kalinski, P., Hunter, O. C., Lotze, M. T. & Amoscato, A. A. Ceramide mediates tumor-induced dendritic cell apoptosis. J. Immunol. 167, 3773\u20133784 (2001).","journal-title":"J. Immunol."},{"key":"1798_CR103","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s12276-023-01018-9","volume":"55","author":"M Lee","year":"2023","unstructured":"Lee, M., Lee, S. Y. & Bae, Y.-S. Functional roles of sphingolipids in immunity and their implication in disease. Exp. Mol. Med. 55, 1110\u20131130 (2023).","journal-title":"Exp. Mol. Med."},{"key":"1798_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-025-02642-2","volume":"24","author":"H Thakkar","year":"2025","unstructured":"Thakkar, H., Vincent, V. & Chaurasia, B. Ceramide signaling in immunity: a molecular perspective. Lipids Health Dis. 24, 225 (2025).","journal-title":"Lipids Health Dis."},{"key":"1798_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02403-1","volume":"11","author":"Y Shi","year":"2025","unstructured":"Shi, Y., Zhang, H. & Miao, C. Metabolic reprogram and T cell differentiation in inflammation: current evidence and future perspectives. Cell Death Discov. 11, 123 (2025).","journal-title":"Cell Death Discov."},{"key":"1798_CR106","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.it.2012.01.010","volume":"33","author":"VA Gerriets","year":"2012","unstructured":"Gerriets, V. A. & Rathmell, J. C. Metabolic pathways in T cell fate and function. Trends Immunol. 33, 168\u2013173 (2012).","journal-title":"Trends Immunol."},{"key":"1798_CR107","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1146\/annurev-immunol-042617-053019","volume":"36","author":"RIK Geltink","year":"2018","unstructured":"Geltink, R. I. K., Kyle, R. L. & Pearce, E. L. Unraveling the complex interplay between T cell metabolism and function. Annu. Rev. Immunol. 36, 461\u2013488 (2018).","journal-title":"Annu. Rev. Immunol."},{"key":"1798_CR108","doi-asserted-by":"publisher","DOI":"10.1172\/JCI148546","volume":"132","author":"M Corrado","year":"2022","unstructured":"Corrado, M. & Pearce, E. L. Targeting memory T cell metabolism to improve immunity. J. Clin. Invest. 132, e148546 (2022).","journal-title":"J. Clin. Invest."},{"key":"1798_CR109","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.cels.2024.11.010","volume":"15","author":"B Feng","year":"2024","unstructured":"Feng, B., Li, R., Li, W. & Tang, L. Metabolic immunoengineering approaches to enhance CD8+ T cell-based cancer immunotherapy. Cell Syst. 15, 1225\u20131244 (2024).","journal-title":"Cell Syst."},{"key":"1798_CR110","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.cmet.2020.09.013","volume":"32","author":"MN Artyomov","year":"2020","unstructured":"Artyomov, M. N. & Van den Bossche, J. Immunometabolism in the single-cell era. Cell Metab. 32, 710\u2013725 (2020).","journal-title":"Cell Metab."},{"key":"1798_CR111","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.cmet.2022.02.003","volume":"34","author":"SH M\u00f8ller","year":"2022","unstructured":"M\u00f8ller, S. H., Hsueh, P.-C., Yu, Y.-R., Zhang, L. & Ho, P.-C. Metabolic programs tailor T cell immunity in viral infection, cancer, and aging. Cell Metab. 34, 378\u2013395 (2022).","journal-title":"Cell Metab."},{"key":"1798_CR112","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1073\/pnas.1014769108","volume":"108","author":"Q Sun","year":"2011","unstructured":"Sun, Q. et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Ntl Acad. Sci. 108, 4129\u20134134 (2011).","journal-title":"Proc. Ntl Acad. Sci."},{"key":"1798_CR113","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41423-023-01064-3","volume":"20","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Regulation of CD8+ T memory and exhaustion by the mTOR signals. Cell. Mol. Immunol. 20, 1023\u20131039 (2023).","journal-title":"Cell. Mol. Immunol."},{"key":"1798_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01255-x","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang, Y. et al. Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells. J. Hematol. Oncol. 15, 38 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"1798_CR115","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/imr.12655","volume":"283","author":"B Raud","year":"2018","unstructured":"Raud, B., McGuire, P. J., Jones, R. G., Sparwasser, T. & Berod, L. Fatty acid metabolism in CD8+ T cell memory: challenging current concepts. Immunol. Rev. 283, 213\u2013231 (2018).","journal-title":"Immunol. Rev."},{"key":"1798_CR116","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.celrep.2018.03.084","volume":"23","author":"C Ecker","year":"2018","unstructured":"Ecker, C. et al. Differential reliance on lipid metabolism as a salvage pathway underlies functional differences of T cell subsets in poor nutrient environments. Cell Rep. 23, 741\u2013755 (2018).","journal-title":"Cell Rep."},{"key":"1798_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2014.06.009","volume":"41","author":"SE Weinberg","year":"2014","unstructured":"Weinberg, S. E. & Chandel, N. S. Futility sustains memory T cells. Immunity 41, 1\u20133 (2014).","journal-title":"Immunity"},{"key":"1798_CR118","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature21379","volume":"543","author":"Y Pan","year":"2017","unstructured":"Pan, Y. et al. Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism. Nature 543, 252\u2013256 (2017).","journal-title":"Nature"},{"key":"1798_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07122-6","volume":"15","author":"Y Zheng","year":"2024","unstructured":"Zheng, Y. et al. Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment. Cell Death Dis. 15, 775 (2024).","journal-title":"Cell Death Dis."},{"key":"1798_CR120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1548234","volume":"16","author":"R Nair","year":"2025","unstructured":"Nair, R. et al. Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies. Front. Immunol. 16, 1548234 (2025).","journal-title":"Front. Immunol."},{"key":"1798_CR121","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2021.12.012","volume":"55","author":"NM Chapman","year":"2022","unstructured":"Chapman, N. M. & Chi, H. Metabolic adaptation of lymphocytes in immunity and disease. Immunity 55, 14\u201330 (2022).","journal-title":"Immunity"},{"key":"1798_CR122","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42634-3","volume":"14","author":"H Wu","year":"2023","unstructured":"Wu, H. et al. Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1\u03b1-mediated glycolytic reprogramming. Nat. Commun. 14, 6858 (2023).","journal-title":"Nat. Commun."},{"key":"1798_CR123","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41590-020-0725-2","volume":"21","author":"SA Vardhana","year":"2020","unstructured":"Vardhana, S. A. et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat. Immunol. 21, 1022\u20131033 (2020).","journal-title":"Nat. Immunol."},{"key":"1798_CR124","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","volume":"42","author":"GJ Martinez","year":"2015","unstructured":"Martinez, G. J. et al. The transcription factor NFAT promotes exhaustion of activated CD8\u207a T cells. Immunity 42, 265\u2013278 (2015).","journal-title":"Immunity"},{"key":"1798_CR125","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/s41590-024-01999-3","volume":"25","author":"RM Peralta","year":"2024","unstructured":"Peralta, R. M. et al. Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism. Nat. Immunol. 25, 2297\u20132307 (2024).","journal-title":"Nat. Immunol."},{"key":"1798_CR126","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s12276-023-01028-7","volume":"55","author":"S-K Seo","year":"2023","unstructured":"Seo, S.-K. & Kwon, B. Immune regulation through tryptophan metabolism. Exp. Mol. Med. 55, 1371\u20131379 (2023).","journal-title":"Exp. Mol. Med."},{"key":"1798_CR127","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70703","volume":"14","author":"Z Lu","year":"2025","unstructured":"Lu, Z. et al. The kynurenine pathway and indole pathway in tryptophan metabolism influence tumor progression. Cancer Med. 14, e70703 (2025).","journal-title":"Cancer Med."},{"key":"1798_CR128","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ccell.2018.02.005","volume":"33","author":"Y Liu","year":"2018","unstructured":"Liu, Y. et al. Tumor-repopulating cells induce PD-1 expression in CD8+ T cells by transferring kynurenine and AhR activation. Cancer Cell 33, 480\u2013494.e7 (2018).","journal-title":"Cancer Cell"},{"key":"1798_CR129","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41590-020-00850-9","volume":"22","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor. Nat. Immunol. 22, 358\u2013369 (2021).","journal-title":"Nat. Immunol."},{"key":"1798_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17750-z","volume":"11","author":"LF Campesato","year":"2020","unstructured":"Campesato, L. F. et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-kynurenine. Nat. Commun. 11, 4011 (2020).","journal-title":"Nat. Commun."},{"key":"1798_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.110298","volume":"265","author":"M Luo","year":"2024","unstructured":"Luo, M. et al. Roles of prostaglandins in immunosuppression. Clin. Immunol. 265, 110298 (2024).","journal-title":"Clin. Immunol."},{"key":"1798_CR132","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-024-07254-x","volume":"629","author":"SB Lacher","year":"2024","unstructured":"Lacher, S. B. et al. PGE(2) limits effector expansion of tumour-infiltrating stem-like CD8(+) T cells. Nature 629, 417\u2013425 (2024).","journal-title":"Nature"},{"key":"1798_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-35350-7","volume":"16","author":"L Wang","year":"2026","unstructured":"Wang, L. et al. The emerging role of SPHK1 at the immune-metabolic interface: a pan-cancer integrative analysis. Sci. Rep. 16, 5528 (2026).","journal-title":"Sci. Rep."},{"key":"1798_CR134","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","volume":"30","author":"X Ma","year":"2019","unstructured":"Ma, X. et al. Cholesterol induces CD8+ T cell exhaustion in the tumor microenvironment. Cell Metab. 30, 143\u2013156.e5 (2019).","journal-title":"Cell Metab."},{"key":"1798_CR135","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41586-018-0597-x","volume":"562","author":"M Song","year":"2018","unstructured":"Song, M. et al. IRE1\u03b1\u2013XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. Nature 562, 423\u2013428 (2018).","journal-title":"Nature"},{"key":"1798_CR136","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41586-024-08071-y","volume":"635","author":"S-M Hwang","year":"2024","unstructured":"Hwang, S.-M. et al. Transgelin 2 guards T cell lipid metabolism and antitumour function. Nature 635, 1010\u20131018 (2024).","journal-title":"Nature"},{"key":"1798_CR137","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.it.2021.06.007","volume":"42","author":"NB Martin-Cofreces","year":"2021","unstructured":"Martin-Cofreces, N. B., Valpuesta, J. M. & Sanchez-Madrid, F. T cell asymmetry and metabolic crosstalk can fine-tune immunological synapses. Trends Immunol. 42, 649\u2013653 (2021).","journal-title":"Trends Immunol."},{"key":"1798_CR138","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.tcb.2013.09.005","volume":"24","author":"NB Martin-Cofreces","year":"2014","unstructured":"Martin-Cofreces, N. B., Baixauli, F. & Sanchez-Madrid, F. Immune synapse: conductor of orchestrated organelle movement. Trends Cell Biol. 24, 61\u201372 (2014).","journal-title":"Trends Cell Biol."},{"key":"1798_CR139","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nature01911","volume":"425","author":"P Guermonprez","year":"2003","unstructured":"Guermonprez, P. et al. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 425, 397\u2013402 (2003).","journal-title":"Nature"},{"key":"1798_CR140","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202350393","volume":"53","author":"D Calzada-Fraile","year":"2023","unstructured":"Calzada-Fraile, D. & Sanchez-Madrid, F. Reprogramming dendritic cells through the immunological synapse: a two-way street. Eur. J. Immunol. 53, e2350393 (2023).","journal-title":"Eur. J. Immunol."},{"key":"1798_CR141","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cytogfr.2017.03.004","volume":"35","author":"JNR Gnanaprakasam","year":"2017","unstructured":"Gnanaprakasam, J. N. R., Sherman, J. W. & Wang, R. MYC and HIF in shaping immune response and immune metabolism. Cytokine Growth Factor Rev. 35, 63\u201370 (2017).","journal-title":"Cytokine Growth Factor Rev."},{"key":"1798_CR142","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1083\/jcb.200203043","volume":"158","author":"SC Bunnell","year":"2002","unstructured":"Bunnell, S. C. et al. T cell receptor ligation induces the formation of dynamically regulated signaling assemblies. J. Cell Biol. 158, 1263\u20131275 (2002).","journal-title":"J. Cell Biol."},{"key":"1798_CR143","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1084\/jem.20051182","volume":"202","author":"G Campi","year":"2005","unstructured":"Campi, G., Varma, R. & Dustin, M. L. Actin and agonist MHC-peptide complex-dependent T cell receptor microclusters as scaffolds for signaling. J. Exp. Med. 202, 1031\u20131036 (2005).","journal-title":"J. Exp. Med."},{"key":"1798_CR144","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1039\/C5IB00032G","volume":"7","author":"E Tabdanov","year":"2015","unstructured":"Tabdanov, E. et al. Micropatterning of TCR and LFA-1 ligands reveals complementary effects on cytoskeleton mechanics in T cells. Integr. Biol. 7, 1272\u20131284 (2015).","journal-title":"Integr. Biol."},{"key":"1798_CR145","doi-asserted-by":"publisher","DOI":"10.3389\/fsysb.2024.1372995","author":"S Schafer","year":"2024","unstructured":"Schafer, S., Chen, K. & Ma, L. Crosstalking with dendritic cells: a path to engineer advanced T cell immunotherapy. Front. Syst. Biol. https:\/\/doi.org\/10.3389\/fsysb.2024.1372995 (2024).","journal-title":"Front. Syst. Biol."},{"key":"1798_CR146","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1083\/jcb.201301004","volume":"202","author":"J Yi","year":"2013","unstructured":"Yi, J. et al. Centrosome repositioning in T cells is biphasic and driven by microtubule end-on capture-shrinkage. J. Cell Biol. 202, 779\u2013792 (2013).","journal-title":"J. Cell Biol."},{"key":"1798_CR147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00235","volume":"3","author":"M Huse","year":"2012","unstructured":"Huse, M. Microtubule-organizing center polarity and the immunological synapse: protein kinase C and beyond. Front. Immunol. 3, 235 (2012).","journal-title":"Front. Immunol."},{"key":"1798_CR148","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1073\/pnas.0706122105","volume":"105","author":"MI Lioudyno","year":"2008","unstructured":"Lioudyno, M. I. et al. Orai1 and STIM1 move to the immunological synapse and are up-regulated during T cell activation. Proc. Natl Acad. Sci. USA. 105, 2011\u20132016 (2008).","journal-title":"Proc. Natl Acad. Sci. USA."},{"key":"1798_CR149","doi-asserted-by":"publisher","first-page":"6296","DOI":"10.4049\/jimmunol.0900613","volume":"183","author":"SA Nicolaou","year":"2009","unstructured":"Nicolaou, S. A. et al. Localization of Kv1.3 channels in the immunological synapse modulates the calcium response to antigen stimulation in T lymphocytes. J. Immunol. 183, 6296\u20136302 (2009).","journal-title":"J. Immunol."},{"key":"1798_CR150","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41589-020-0533-x","volume":"16","author":"JM Ghergurovich","year":"2020","unstructured":"Ghergurovich, J. M. et al. A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway. Nat. Chem. Biol. 16, 731\u2013739 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"1798_CR151","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.cell.2021.12.039","volume":"185","author":"J Lotscher","year":"2022","unstructured":"Lotscher, J. et al. Magnesium sensing via LFA-1 regulates CD8+ T cell effector function. Cell. 185, 585\u2013602.e29 (2022).","journal-title":"Cell."},{"key":"1798_CR152","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12956","volume":"92","author":"SS Kolan","year":"2020","unstructured":"Kolan, S. S. et al. Cellular metabolism dictates T cell effector function in health and disease. Scand. J. Immunol. 92, e12956 (2020).","journal-title":"Scand. J. Immunol."},{"key":"1798_CR153","doi-asserted-by":"publisher","first-page":"14883","DOI":"10.1073\/pnas.0600914103","volume":"103","author":"J Combs","year":"2006","unstructured":"Combs, J. et al. Recruitment of dynein to the Jurkat immunological synapse. Proc. Natl Acad. Sci. USA. 103, 14883\u201314888 (2006).","journal-title":"Proc. Natl Acad. Sci. USA."},{"key":"1798_CR154","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1409238","volume":"15","author":"F Schuurmans","year":"2024","unstructured":"Schuurmans, F., Wagemans, K. E., Adema, G. J. & Cornelissen, L. A. M. Tumor glucose metabolism and the T cell glycocalyx: implication for T cell function. Front. Immunol. 15, 1409238 (2024).","journal-title":"Front. Immunol."},{"key":"1798_CR155","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41586-018-0597-x","volume":"562","author":"M Song","year":"2018","unstructured":"Song, M. et al. IRE1alpha-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. Nature. 562, 423\u2013428 (2018).","journal-title":"Nature."},{"key":"1798_CR156","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","volume":"109","author":"K Fischer","year":"2007","unstructured":"Fischer, K. et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 109, 3812\u20133819 (2007).","journal-title":"Blood."},{"key":"1798_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06371-0","volume":"7","author":"D Gavriliouk","year":"2017","unstructured":"Gavriliouk, D. et al. Regulation of Orai1\/STIM1 mediated I(CRAC) by intracellular pH. Sci. Rep. 7, 9829 (2017).","journal-title":"Sci. Rep."},{"key":"1798_CR158","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11302-012-9309-4","volume":"8","author":"H Zimmermann","year":"2012","unstructured":"Zimmermann, H., Zebisch, M. & Strater, N. Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal. 8, 437\u2013502 (2012).","journal-title":"Purinergic Signal."},{"key":"1798_CR159","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1182\/blood.V90.4.1600","volume":"90","author":"S Huang","year":"1997","unstructured":"Huang, S., Apasov, S., Koshiba, M. & Sitkovsky, M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood. 90, 1600\u20131610 (1997).","journal-title":"Blood."},{"key":"1798_CR160","doi-asserted-by":"publisher","first-page":"e728","DOI":"10.1111\/j.1365-2567.2009.03075.x","volume":"128","author":"C Linnemann","year":"2009","unstructured":"Linnemann, C. et al. Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling. Immunology. 128, e728\u2013e737 (2009).","journal-title":"Immunology."},{"key":"1798_CR161","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/intimm\/dxs004","volume":"24","author":"N Feldmeyer","year":"2012","unstructured":"Feldmeyer, N. et al. Arginine deficiency leads to impaired cofilin dephosphorylation in activated human T lymphocytes. Int. Immunol. 24, 303\u2013313 (2012).","journal-title":"Int. Immunol."},{"key":"1798_CR162","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cellimm.2005.01.004","volume":"232","author":"AH Zea","year":"2004","unstructured":"Zea, A. H. et al. L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell Immunol. 232, 21\u201331 (2004).","journal-title":"Cell Immunol."},{"key":"1798_CR163","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/ni.3439","volume":"17","author":"M Swamy","year":"2016","unstructured":"Swamy, M. et al. Glucose and glutamine fuel protein O-GlcNAcylation to control T cell self-renewal and malignancy. Nat. Immunol. 17, 712\u2013720 (2016).","journal-title":"Nat. Immunol."},{"key":"1798_CR164","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1083\/jcb.147.2.447","volume":"147","author":"PW Janes","year":"1999","unstructured":"Janes, P. W., Ley, S. C. & Magee, A. I. Aggregation of lipid rafts accompanies signaling via the T cell antigen receptor. J. Cell Biol. 147, 447\u2013461, https:\/\/doi.org\/10.1083\/jcb.147.2.447 (1999).","journal-title":"J. Cell Biol."},{"key":"1798_CR165","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41589-022-01017-3","volume":"18","author":"SA Lim","year":"2022","unstructured":"Lim, S. A., Su, W., Chapman, N. M. & Chi, H. Lipid metabolism in T cell signaling and function. Nat. Chem. Biol. 18, 470\u2013481 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"1798_CR166","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nature17412","volume":"531","author":"W Yang","year":"2016","unstructured":"Yang, W. et al. Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism. Nature. 531, 651\u2013655 (2016).","journal-title":"Nature."},{"key":"1798_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22967-7","volume":"12","author":"NM Schmidt","year":"2021","unstructured":"Schmidt, N. M. et al. Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint. Nat. Commun. 12, 2814 (2021).","journal-title":"Nat. Commun."},{"key":"1798_CR168","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2118816119","volume":"119","author":"KN Kremer","year":"2022","unstructured":"Kremer, K. N. et al. LPA suppresses T cell function by altering the cytoskeleton and disrupting immune synapse formation. Proc. Natl Acad. Sci. USA. 119, e2118816119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA."},{"key":"1798_CR169","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/730209","volume":"2011","author":"I Levitan","year":"2011","unstructured":"Levitan, I. & Shentu, T. P. Impact of oxLDL on cholesterol-rich membrane rafts. J Lipids. 2011, 730209 (2011).","journal-title":"J Lipids."},{"key":"1798_CR170","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","volume":"21","author":"ZE Stine","year":"2022","unstructured":"Stine, Z. E., Schug, Z. T., Salvino, J. M. & Dang, C. V. Targeting cancer metabolism in the era of precision oncology. Nat. Rev. Drug Discov. 21, 141\u2013162 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1798_CR171","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02119-3","volume":"23","author":"M Tufail","year":"2024","unstructured":"Tufail, M., Jiang, C.-H. & Li, N. Altered metabolism in cancer: insights into energy pathways and therapeutic targets. Mol. Cancer. 23, 203 (2024).","journal-title":"Mol. Cancer."},{"key":"1798_CR172","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00646-1","volume":"12","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment. Biomarker Res. 12, 96 (2024).","journal-title":"Biomarker Res."},{"key":"1798_CR173","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-02106-z","volume":"10","author":"ZA Miller","year":"2024","unstructured":"Miller, Z. A. et al. GLUT1 inhibitor BAY-876 induces apoptosis and enhances anti-cancer effects of bitter receptor agonists in head and neck squamous carcinoma cells. Cell Death Discov. 10, 339 (2024).","journal-title":"Cell Death Discov."},{"key":"1798_CR174","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14141-9","volume":"25","author":"M Hayashi","year":"2025","unstructured":"Hayashi, M. et al. GLUT1 inhibition by BAY-876 induces metabolic changes and cell death in human colorectal cancer cells. BMC Cancer. 25, 716 (2025).","journal-title":"BMC Cancer."},{"key":"1798_CR175","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00280-012-2045-1","volume":"71","author":"LE Raez","year":"2013","unstructured":"Raez, L. E. et al. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 71, 523\u2013530 (2013).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"1798_CR176","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1158\/1078-0432.CCR-23-0036","volume":"29","author":"A Mohan","year":"2023","unstructured":"Mohan, A. et al. Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: preclinical evaluation and phase Ib multicenter clinical trial (BilT-04). Clin. Cancer Res. 29, 2394\u20132400 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1798_CR177","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/s41416-020-01230-8","volume":"124","author":"S Yao","year":"2021","unstructured":"Yao, S. et al. Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. Br. J. Cancer. 124, 1533\u20131539 (2021).","journal-title":"Br. J. Cancer."},{"key":"1798_CR178","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1158\/1541-7786.MCR-11-0359","volume":"10","author":"EV Sheveleva","year":"2012","unstructured":"Sheveleva, E. V. et al. Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells. Mol. Cancer Res. 10, 392\u2013400 (2012).","journal-title":"Mol. Cancer Res."},{"key":"1798_CR179","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1182\/blood-2014-04-570044","volume":"124","author":"PM Barr","year":"2014","unstructured":"Barr, P. M. et al. Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 124, 1259\u20131265 (2014).","journal-title":"Blood."},{"key":"1798_CR180","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1038\/onc.2015.60","volume":"34","author":"L Sleire","year":"2015","unstructured":"Sleire, L. et al. Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc\u2212, leading to glutathione depletion. Oncogene. 34, 5951\u20135959 (2015).","journal-title":"Oncogene."},{"key":"1798_CR181","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.7150\/jca.24488","volume":"9","author":"X Lian","year":"2018","unstructured":"Lian, X. et al. Anticancer properties of fenofibrate: a repurposing use. J. Cancer. 9, 1527\u20131537 (2018).","journal-title":"J. Cancer."},{"key":"1798_CR182","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0308-4","volume":"5","author":"SM Steggerda","year":"2017","unstructured":"Steggerda, S. M. et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J. Immunother. Cancer 5, 101 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"1798_CR183","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2023-000249","volume":"3","author":"A Naing","year":"2024","unstructured":"Naing, A. et al. First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours. BMJ Oncol. 3, e000249 (2024).","journal-title":"BMJ Oncol."},{"key":"1798_CR184","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1158\/1078-0432.CCR-22-3911","volume":"29","author":"CM Kelly","year":"2023","unstructured":"Kelly, C. M. et al. A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma. Clin. Cancer Res. 29, 2043\u20132051 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1798_CR185","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00370","volume":"8","author":"E Fox","year":"2018","unstructured":"Fox, E. et al. Indoximod: an immunometabolic adjuvant that empowers T cell activity in cancer. Front. Oncol. 8, 370 (2018).","journal-title":"Front. Oncol."},{"key":"1798_CR186","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100797","volume":"34","author":"G Falchook","year":"2021","unstructured":"Falchook, G. et al. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine. 34, 100797 (2021).","journal-title":"EClinicalMedicine."},{"key":"1798_CR187","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1158\/2159-8290.CD-16-0716","volume":"6","author":"K Okkenhaug","year":"2016","unstructured":"Okkenhaug, K., Graupera, M. & Vanhaesebroeck, B. Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy. Cancer Discov. 6, 1090\u20131105 (2016).","journal-title":"Cancer Discov."},{"key":"1798_CR188","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.1158\/1078-0432.CCR-21-1204","volume":"27","author":"JJ Harding","year":"2021","unstructured":"Harding, J. J. et al. A phase I dose-escalation and expansion study of telaglenastat in patients with advanced or metastatic solid tumors. Clin. Cancer Res. 27, 4994\u20135003 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1798_CR189","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s10637-020-00899-1","volume":"38","author":"DC Smith","year":"2020","unstructured":"Smith, D. C. et al. A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. Invest. New Drugs. 38, 1421\u20131429 (2020).","journal-title":"Invest. New Drugs."},{"key":"1798_CR190","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26134-w","volume":"12","author":"E Schneider","year":"2021","unstructured":"Schneider, E. et al. CD73-mediated adenosine production by CD8 T cell-derived extracellular vesicles constitutes an intrinsic mechanism of immune suppression. Nat. Commun. 12, 5911 (2021).","journal-title":"Nat. Commun."},{"key":"1798_CR191","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jtho.2022.12.021","volume":"18","author":"DW Kim","year":"2023","unstructured":"Kim, D. W. et al. CD73 inhibitor oleclumab plus osimertinib in previously treated patients with advanced T790M-negative EGFR-mutated NSCLC: a brief report. J. Thorac. Oncol. 18, 650\u2013656 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"1798_CR192","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1242544","volume":"5","author":"C Cubillos-Zapata","year":"2016","unstructured":"Cubillos-Zapata, C. et al. Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia. Oncoimmunology 5, e1242544 (2016).","journal-title":"Oncoimmunology"},{"key":"1798_CR193","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1182\/blood.2023020554","volume":"143","author":"D Papazoglou","year":"2024","unstructured":"Papazoglou, D. et al. Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial. Blood. 143, 57\u201363 (2024).","journal-title":"Blood."},{"key":"1798_CR194","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1172\/JCI89756","volume":"127","author":"M Long","year":"2017","unstructured":"Long, M. et al. Ibrutinib treatment improves T cell number and function in CLL patients. J. Clin. Invest. 127, 3052\u20133064 (2017).","journal-title":"J. Clin. Invest."},{"key":"1798_CR195","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1691392","volume":"16","author":"B Kuang","year":"2025","unstructured":"Kuang, B. et al. Celecoxib in oncology: targeting the COX-2\/PGE2 axis to reprogram the tumor immune microenvironment and enhance multimodal therapy. Front. Pharmacol. 16, 1691392 (2025).","journal-title":"Front. Pharmacol."},{"key":"1798_CR196","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1158\/0008-5472.CAN-16-2686","volume":"77","author":"M Beloueche-Babari","year":"2017","unstructured":"Beloueche-Babari, M. et al. MCT1 inhibitor AZD3965 increases mitochondrial metabolism, facilitating combination therapy and noninvasive magnetic resonance spectroscopy. Cancer Res. 77, 5913\u20135924 (2017).","journal-title":"Cancer Res."},{"key":"1798_CR197","doi-asserted-by":"publisher","first-page":"993","DOI":"10.7150\/thno.104872","volume":"15","author":"J Liu","year":"2025","unstructured":"Liu, J., Li, X., Li, Y., Gong, Q. & Luo, K. Metformin-based nanomedicines for reprogramming tumor immune microenvironment. Theranostics. 15, 993\u20131016 (2025).","journal-title":"Theranostics."},{"key":"1798_CR198","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1158\/2767-9764.CRC-22-0260","volume":"4","author":"V Subbiah","year":"2024","unstructured":"Subbiah, V. et al. Phase I study of mTORC1\/2 inhibitor sapanisertib (CB-228\/TAK-228) in combination with metformin in patients with mTOR\/AKT\/PI3K pathway alterations and advanced solid malignancies. Cancer Res. Commun. 4, 378\u2013387 (2024).","journal-title":"Cancer Res. Commun."},{"key":"1798_CR199","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s10637-013-0047-4","volume":"32","author":"EM Dunbar","year":"2014","unstructured":"Dunbar, E. M. et al. Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Invest. New Drugs. 32, 452\u2013464 (2014).","journal-title":"Invest. New Drugs."},{"key":"1798_CR200","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00535-1","volume":"13","author":"A Van der Vreken","year":"2024","unstructured":"Van der Vreken, A. et al. Fueling CARs: metabolic strategies to enhance CAR T-cell therapy. Exp. Hematol. Oncol. 13, 66 (2024).","journal-title":"Exp. Hematol. Oncol."},{"key":"1798_CR201","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107928","volume":"220","author":"B Perucha","year":"2025","unstructured":"Perucha, B. et al. Reprogramming CAR-T cells: targeting SLC transporters for tumor microenvironment adaptation. Pharmacol. Res. 220, 107928 (2025).","journal-title":"Pharmacol. Res."},{"key":"1798_CR202","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","volume":"22","author":"Y Guo","year":"2021","unstructured":"Guo, Y. et al. Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity. Nat. Immunol. 22, 746\u2013756 (2021).","journal-title":"Nat. Immunol."},{"key":"1798_CR203","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40886-7","volume":"14","author":"J Han","year":"2023","unstructured":"Han, J. et al. Metabolic glycan labeling immobilizes dendritic cell membrane and enhances antitumor efficacy of dendritic cell vaccine. Nat. Commun. 14, 5049 (2023).","journal-title":"Nat. Commun."},{"key":"1798_CR204","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.immuni.2019.09.003","volume":"51","author":"EH Ma","year":"2019","unstructured":"Ma, E. H. et al. Metabolic profiling using stable isotope tracing reveals distinct patterns of glucose utilization by physiologically activated CD8+ T cells. Immunity. 51, 856\u2013870.e5 (2019).","journal-title":"Immunity."},{"key":"1798_CR205","doi-asserted-by":"publisher","first-page":"555a","DOI":"10.1016\/j.bpj.2023.11.3357","volume":"123","author":"N Paillon","year":"2024","unstructured":"Paillon, N., Ung, T. P. L., Dogniaux, S., Stringari, C. & Hivroz, C. Label-free single-cell live imaging reveals fast metabolic switch in T lymphocytes. Biophys. J. 123, 555a\u2013556a (2024).","journal-title":"Biophys. J."},{"key":"1798_CR206","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202500098","volume":"8","author":"F Moresi","year":"2025","unstructured":"Moresi, F. et al. Microphysiological systems in cancer research: advancing immunotherapy through tumor microenvironment-integrated organ-on-chip models. Adv. Ther. 8, e00098 (2025).","journal-title":"Adv. Ther."},{"key":"1798_CR207","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-95031-9","volume":"15","author":"AI Morrison","year":"2025","unstructured":"Morrison, A. I. et al. Functional organotypic human lymph node model with native immune cells benefits from fibroblastic reticular cell enrichment. Sci. Rep. 15, 12233 (2025).","journal-title":"Sci. Rep."},{"key":"1798_CR208","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02479-4","volume":"24","author":"F Dabbagh Moghaddam","year":"2025","unstructured":"Dabbagh Moghaddam, F. et al. Advances in engineering immune-tumor microenvironments on-a-chip: integrative microfluidic platforms for immunotherapy and drug discovery. Mol. Cancer. 24, 271 (2025).","journal-title":"Mol. Cancer."},{"key":"1798_CR209","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1454720","volume":"15","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. Companion diagnostics and predictive biomarkers for PD-1\/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma. Front. Immunol. 15, 1454720 (2024).","journal-title":"Front. Immunol."},{"key":"1798_CR210","volume":"1","author":"Y-H Wang","year":"2025","unstructured":"Wang, Y.-H., Wang, L. & Ho, P.-C. Decoding immunometabolism with next-generation tools: lessons from dendritic cells and T cells. EMBO J. 1, 16 (2025).","journal-title":"EMBO J."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01798-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01798-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01798-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:03:02Z","timestamp":1788339782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01798-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":210,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["1798"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01798-w","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}